On February 27, 2026, Ascendis Pharma A/S announced FDA approval for YUVIWEL, the first weekly treatment to increase growth in children with achondroplasia. This approval is part of the FDA's Accelerated Approval Program, with continued approval dependent on confirmatory trials.